Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study.

Wilson, Sarah; Calocer, Floriane; Rollot, Fabien; Fauvernier, Mathieu; Remontet, Laurent; Tron, Laure; Vukusic, Sandra; Le Page, Emmanuelle; Debouverie, Marc; Ciron, Jonathan; Ruet, Aurélie; De Sèze, Jérôme; Zephir, Hélène; Moreau, Thibault; Lebrun-Frénay, Christine; Laplaud, David-Axel; Clavelou, Pierre; Labauge, Pierre; Berger, Eric; Pelletier, Jean; Heinzlef, Olivier; Thouvenot, Eric; Camdessanché, Jean Philippe; Leray, Emmanuelle; Dejardin, Olivier; Defer, Gilles

Wilson, Sarah; Calocer, Floriane; Rollot, Fabien; Fauvernier, Mathieu; Remontet, Laurent; Tron, Laure; Vukusic, Sandra; Le Page, Emmanuelle; Debouverie, Marc; Ciron, Jonathan; Ruet, Aurélie; De Sèze, Jérôme; Zephir, Hélène; Moreau, Thibault; Lebrun-Frénay, Christine; Laplaud, David-Axel; Clavelou, Pierre; Labauge, Pierre; Berger, Eric; Pelletier, Jean; Heinzlef, Olivier; Thouvenot, Eric; Camdessanché, Jean Philippe; Leray, Emmanuelle; Dejardin, Olivier; Defer, Gilles.

Afiliación

Wilson S; UNICAEN, CHU de Caen, INSERM U1086 ANTICIPE, Pôle de Recherche, Normandy University, Caen 14000, France.
Calocer F; Department of Neurology, UNICAEN, Normandy University, MS Expert Center, CHU de Caen Normandy, Caen 14000, France.
Rollot F; Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69000, France.
Fauvernier M; Hospices Civils de Lyon, Hôpital Neurologique, Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Bron 69500, France.
Remontet L; Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, Lyon 69000, France.
Tron L; EUGENE DEVIC EDMUS Foundation Against Multiple Sclerosis, State-Approved Foundation, Bron, France.
Vukusic S; Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon 69000, France.
Le Page E; Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon 69000, France.
Debouverie M; Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon 69000, France.
Ciron J; Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon 69000, France.
Ruet A; UNICAEN, CHU de Caen, INSERM U1086 ANTICIPE, Pôle de Recherche, Normandy University, Caen 14000, France.
De Sèze J; Université de Lyon, Université Claude Bernard Lyon 1, Lyon 69000, France.
Zephir H; Hospices Civils de Lyon, Hôpital Neurologique, Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Bron 69500, France.
Moreau T; Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, Lyon 69000, France.
Lebrun-Frénay C; EUGENE DEVIC EDMUS Foundation Against Multiple Sclerosis, State-Approved Foundation, Bron, France.
Laplaud DA; CHU Pontchaillou, CIC1414 INSERM, Rennes F-35000, France.
Clavelou P; Department of Neurology, Nancy University Hospital, Nancy, France.
Labauge P; Université de Lorraine, APEMAC, Nancy F-54000, France.
Berger E; Department of Neurology, CHU de Toulouse, CRC-SEP, Toulouse Cedex 9 F-31059, France.
Pelletier J; Université Toulouse III, Infinity, INSERM UMR1291 - CNRS UMR5051, Toulouse Cedex 3 F-31024, France.
Heinzlef O; Univ. Bordeaux, Bordeaux F-33000, France.
Thouvenot E; INSERM U1215, Neurocentre Magendie, Bordeaux F-33000, France.
Camdessanché JP; Department of Neurology, CHU de Bordeaux, CIC Bordeaux CIC1401, Bordeaux F-33000, France.
Leray E; Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, CIC 1434, INSERM 1434, Strasbourg F-67000, France.
Dejardin O; CHU Lille, CRCSEP Lille, Univ Lille, U1172, Lille F-59000, France.
Defer G; Department of Neurology, CHU de Dijon, EA4184, Dijon F-21000, France.

Lancet Reg Health Eur ; 24: 100542, 2023 Jan.

Article en En | MEDLINE | ID: mdl-36426377

Palabras clave

AIC, Akaike Information Criteria; CI, confidence interval; DMT, disease modifying therapy; EDR, excess death rate; Excess mortality; Flexible model; MS, multiple sclerosis; Multiple sclerosis; Net survival; OFSEP, Observatoire Français de la Sclérose en Plaques; Observational cohort study; PPMS, primary progressive multiple sclerosis; R-MS, relapsing onset multiple sclerosis; SES, socio-economic status; Socio-economic status

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google